Shares of drug developer Wave Life Sciences (WVE.O) rise 3.6% to $13.40
Co says it has regained full rights to WVE-006, its experimental genetic disorder therapy, from GSK (GSK.L)
WVE plans to engage with the US FDA on a potential accelerated approval pathway, with regulatory feedback expected mid-2026 for the therapy
Co is testing the therapy as a potential treatment to alpha-1 antitrypsin deficiency, a genetic disorder that can lead to serious lung and liver diseases due to low levels of the protein alpha-1 antitrypsin
Data from its ongoing clinical trial testing WVE-006 is on track for Q1 of 2026, co says
“Decision is due to strategic re-prioritization by partner GSK vs. data driven as no new data were disclosed”- Jefferies
“We think it makes sense as GSK may be more interested in large indications, such as COPD”- Truist
WVE rose 37.4% last year

IBBQ

SBIO

Reuters

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Wave Life Sciences

Invesco Biotechnology & Genome ETF

Bioshares Biotech Clinical Trials Fd

SPDR S&P Biotech

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

BUZZ-Wave Life rises after regaining full rights to genetic disorder therapy from GSK